Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock

Protagonist Therapeutics CEO Dinesh Patel sold a significant amount of stock in his company on two days in August 2026. The CEO, Dr. Patel, sold 100,000 shares, totaling approximately $14.9 million, through the exercise of stock options as part of a predetermined trading plan. The sale took place at weighted average prices ranging from $148.52 to $149.11 per share.

On August 10, Dr. Patel sold 65,761 shares at $149.11 per share, while on August 11, he sold an additional 34,239 shares at $148.52 per share. The PTGX stock was trading near its 52-week high of $152.70, marking a remarkable 168% gain over the past year. Analysts suggest that the stock is currently overvalued. Dr. Patel had previously exercised options to acquire the 100,000 shares bought on these two days, with an exercise price of $21.58 per share, totaling around $2.16 million.

Following these transactions, Dr. Patel now personally owns 523,478 shares of Protagonist Therapeutics common stock. Protagonist Therapeutics reported strong financial results in their second quarter of 2026, with GAAP earnings per share of $2.29 and license and collaboration revenue of $213 million, largely due to a $192 million recognition from Takeda.

The stock received positive ratings and price targets from several analysts, indicating optimism about the company's potential drug development.